HANSOH PHARMA's Self-Developed B7-H3-Targeting ADC HS-20093 in Combination with Adebelimumab Granted Breakthrough Therapy Designation by NMPA

Stock News

昨天

HANSOH PHARMA (03692) announced that on April 16, 2026, its self-developed B7-H3-targeting antibody-drug conjugate (ADC) HS-20093 for injection, in combination with adebelimumab, has been approved by the National Medical Products Administration (NMPA) for inclusion in the Breakthrough Therapy Drug program. The intended indication is for the treatment of driver gene-negative locally advanced or metastatic non-squamous non-small cell lung cancer in patients who have progressed or relapsed after prior platinum-based chemotherapy.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1190790439"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1190790439\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1190790439?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-16 19:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190790439","market":"nz","top_or_hot":-1,"title":"HANSOH PHARMA's Self-Developed B7-H3-Targeting ADC HS-20093 in Combination with Adebelimumab Granted Breakthrough Therapy Designation by NMPA","media":"Stock News","content":"<p>HANSOH PHARMA (03692) announced that on April 16, 2026, its self-developed B7-H3-targeting antibody-drug conjugate (ADC) HS-20093 for injection, in combination with adebelimumab, has been approved by the National Medical Products Administration (NMPA) for inclusion in the Breakthrough Therapy Drug program. The intended indication is for the treatment of driver gene-negative locally advanced or metastatic non-squamous non-small cell lung cancer in patients who have progressed or relapsed after prior platinum-based chemotherapy.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANSOH PHARMA's Self-Developed B7-H3-Targeting ADC HS-20093 in Combination with Adebelimumab Granted Breakthrough Therapy Designation by NMPA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANSOH PHARMA's Self-Developed B7-H3-Targeting ADC HS-20093 in Combination with Adebelimumab Granted Breakthrough Therapy Designation by NMPA\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-04-16 19:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>HANSOH PHARMA (03692) announced that on April 16, 2026, its self-developed B7-H3-targeting antibody-drug conjugate (ADC) HS-20093 for injection, in combination with adebelimumab, has been approved by the National Medical Products Administration (NMPA) for inclusion in the Breakthrough Therapy Drug program. The intended indication is for the treatment of driver gene-negative locally advanced or metastatic non-squamous non-small cell lung cancer in patients who have progressed or relapsed after prior platinum-based chemotherapy.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心資產","start_time":0,"source_url":"","article_id":"1190790439","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190790439","pubTimestamp":1776339378,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HANSOH PHARMA (03692) announced that on April 16, 2026, its self-developed B7-H3-targeting antibody-drug conjugate (ADC) HS-20093 for injection, in combination with adebelimumab, has been approved by...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1589":"北水核心资产","BK1583":"高瓴概念","03692":"翰森制药","BK1191":"制药"},"translate_title":"翰森制药自研B7-H3靶向ADC HS-20093联合阿德贝利木单抗获NMPA突破性疗法认定","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"HANSOH PHARMA (03692) announced that on April 16, 2026, its self-developed B7-H3-targeting antibody-drug conjugate (ADC) HS-20093 for injection, in combination with adebelimumab, has been approved by the National Medical Products Administration (NMPA) for inclusion in the Breakthrough Therapy Drug program. The intended indication is for the treatment of driver gene-negative locally advanced or metastatic non-squamous non-small cell lung cancer in patients who have progressed or relapsed after prior platinum-based chemotherapy.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}